<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15140">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142608</url>
  </required_header>
  <id_info>
    <org_study_id>BR55-105</org_study_id>
    <nct_id>NCT02142608</nct_id>
  </id_info>
  <brief_title>A Pilot Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer</brief_title>
  <official_title>A Pilot Clinical Trial Using BR55 Ultrasound Contrast Agent in the Assessment of Prostate Cancer by Molecular Imaging of VEGFR2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bracco Diagnostics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bracco Diagnostics, Inc</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot study to evaluate the sensitivity and specificity of BR55 targeting for prostate
      cancer nodules with Gleason score greater than or equal to 7.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Sensitivity and specificity of BR55</measure>
    <time_frame>Within 30 minutes after administration of BR55</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using a visual score of ultrasound molecular imaging (USMI) when compared to histopathology results, the sensitivity and specificity of BR55 targeting for prostate cancer nodules with a gleason score that is greater than or equal to 7 will be an outcome measure assessed in this study</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>BR55</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BR55, a new ultrasound contrast agent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BR55</intervention_name>
    <arm_group_label>BR55</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male, age between 50-70 years old

          -  Increased PSA level &gt;4 ng/mL

          -  Known prostate cancer

          -  Scheduled for prostatectomy not earlier than 3 days and not later than 30 days
             following BR55 administration (with the exception of training cases where this
             requirement is not applicable)

          -  Provides written informed consent and willing to comply with protocol requirements

        Exclusion Criteria:

          -  Documented acute prostatitis or urinary tract infections

          -  Known to suffer from stable angina pectoris and/or proven coronary disease, or have
             symptoms suspicious of coronary disease

          -  History of any clinically unstable cardiac condition including class III/IV cardiac
             failure or right-to left shunts

          -  Severe cardiac rhythm disorders within the last 7 days

          -  Severe pulmonary hypertension or uncontrolled systemic hypertension or respiratory
             distress syndrome

          -  Received a prostate biopsy procedure within 30 days before admission into the study

          -  Determined by investigator to be clinically unsuitable for the study

          -  Participating in a concurrent clinical trial or has participated in another clinical
             trial with an investigational compound within the past 30 days
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Luigia Storto, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Bracco Diagnostics, Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juergen Willmann, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Jannu</last_name>
    <phone>609-514-2554</phone>
    <email>annSharon.jannu@diag.bracco.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 20, 2014</lastchanged_date>
  <firstreceived_date>May 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Ultrasound Imaging</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
